What is Everolimus?

Category: Prescription Drugs

Most popular types: Afinitor Certican Zortress

false

Everolimus is an antineoplastic agent used in the treatment of advanced renal cell cancer, after not having therapeutic response with sunitinib or sorafenib. It is also used as an immunosuppressant following solid organ transplant.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Breast cancer 2 2
Kidney transplant 2 1
Neuroendocrine tumor 2 7
Angiomyolipomatosis 1 1
Basal cell skin cancer 1 1

Show all 15 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 5
Moderate 3
Mild 6
None 4

Commonly reported side effects and conditions associated with Everolimus

Side effect Patients Percentage
Mouth sores (ulcers) 4
Decreased appetite 2
Dry skin 2
Fatigue 2
Hair loss 2
Decreased sex drive (libido) 1

Show all 26 reported side effects

Dosages

Based on patients currently taking Everolimus

Dosage Patients Percentage
1.5 mg twice daily 1
5 mg daily 1
70 mg daily 1

Why patients stopped taking Everolimus

Multiple reasons could be selected

Reason Patients Percentage
Doctor's advice 3
Side effects too severe 3
Did not seem to work 2
Course of treatment ended 1
Other 1
See all 7 patients who've stopped taking Everolimus

Duration

Currently taking Everolimus

Duration Patients Percentage
1 - 2 years 1
5 - 10 years 2

Stopped taking Everolimus

Duration Patients Percentage
1 - 6 months 4
6 months - 1 year 2
1 - 2 years 1
Adherence
Adherence Evaluations Percentage
Always 18
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 1
Somewhat hard to take 0
A little hard to take 1
Not at all hard to take 16
Cost per month
Cost per month Evaluations Percentage
$200+ 1
$100-199 0
$50-99 7
$25-49 1
< $25 2
Not specified 7

What people switch to and from

Patients started taking Everolimus after stopping:

Treatment Patients Percentage
Capecitabine (Xeloda) 1
Letrozole (Femara) 1
Nivolumab (Opdivo) 1
Octreotide (Sandostatin) 1
Sunitinib (Sutent) 1

Patients stopped taking Everolimus and switched to:

Treatment Patients Percentage
Capecitabine (Xeloda) 1
Palbociclib (Ibrance) 1
Temozolomide (Temodar) 1
Last updated:
There are no evaluations for Everolimus.